Back

EBV-positive Hodgkin lymphoma with immunosuppressive microenvironment during IL-23 inhibitor therapy for psoriasis

Shah, B.; Franco-Barraza, J.; Cai, K.; Dmitrieva, M.; Messmer, M.; Yang, Y.; Wasik, M.; Cukierman, E.; Nejati, R.

2025-04-11 hematology
10.1101/2025.04.08.25325422 medRxiv
Show abstract

We report the initial case of EBV-positive classic Hodgkin lymphoma (cHL) after guselkumab therapy for psoriasis. High-plex spatial proteomic analysis showed a Th2-polarized immunosuppressive tumor microenvironment, indicating immune reprogramming from IL-23 inhibition might have triggered the onset of EBV-positive cHL.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.